Zusammenfassung
Trotz den heute zur Verfügung stehenden Therapiemöglichkeiten besitzen maligne Gliome weiterhin eine schlechte Prognose. Daher besteht ein dringender Bedarf zur Evaluierung neuer Therapiekonzepte, die auf einem besseren molekularen Verständnis der Onkogenese maligner Gliome basieren. Verschiedene Ansätze molekularer Therapien bei malignen Gliomen werden in präklinischen und klinischen Studien auf ihre Wirksamkeit und Anwendbarkeit überprüft. Dazu zählen vor allem selektiv wirkende klein-molekulare Inhibitoren der Signaltransduktion und die Gen-Therapie. Viele Wachstumsfaktoren, Wachstumsfaktor-Rezeptoren – in der Regel Rezeptor-Tyrosinkinasen – und die mit dem Rezeptor assoziierten intrazellulären Signalwege sind ganz entscheidend in der Onkogenese von Gliomen beteiligt. Verschiedenste klein-molekulare Substanzen, die selektiv mit Molekülen dieser Signaltransduktionswege interferieren, werden momentan in präklinischen und klinischen Studien untersucht. Verschiedene Ansätze der Gen-Therapie zeigten in experimentellen Studien zu malignen Gliomen antitumorale Wirksamkeit. Erste klinische Studien zur Gen-Therapie dieser Tumore wurden in den 90er Jahren begonnen, in denen die retrovirale Herpes-Simplex-Thymidinkinase- (HSV-Tk-) Gen-Therapie am häufigsten angewandt wurde. Die entscheidende Hürde für eine erfolgreiche klinische Gen-Therapie ist der effiziente Gentransfer in die Tumorzelle. Aus diesem Grund wurden in den letzten Jahren neue Gentransfer-Systeme entwickelt. Diese basieren einerseits auf Adeno-, Adeno-assoziierten-, Herpes- and Lentiviren, andererseits auf Träger-Zell-Systeme, wie neurale und endotheliale Vorläuferzellen. Zusätzlich wurden in den letzten Jahren Antisense-Technologien entwickelt und bereits klinisch durch kontinuierliche intratumorale Applikation getestet (z. B. Antisense-TGF-β). Diese Arbeit beschreibt einige neue Entwicklungen molekularer Therapien für maligne Gliome, wobei der Fokus auf klein-molekularen Inhibitoren und Gentherapie-Konzepten liegt.
Summary
Due to the dismal prognosis of malignant glioma with currently available therapies there is an urgent need for new treatments based on a better molecular understanding of gliomagenesis. Several concepts of molecular therapies for malignant glioma are currently being studied in preclinical and clinical settings, including small molecules targeting specific receptor-mediated signaling pathways and gene therapy. Many growth factors, growth factor receptors – usually receptor tyrosine kinasesand receptor-associated signaling pathways are critically involved in gliomagenesis. Numerous selective inhibitors, which specifically block such molecules, are currently evaluated for clinical applicability. Several gene therapy approaches have shown antitumor efficacy in experimental studies, and the first clinical trials for the treatment of malignant glioma were conducted in the 1990s. In clinical trials, retroviral herpes-simplex-thymidinkinase- (HSV-Tk-) gene therapy has been the pioneering and most commonly used approach. However, efficient gene delivery into the tumor cells still remains the crucial obstacle for successful clinical gene therapy. During the past few years a number of new gene transfer vectors based on adeno-, adeno-associated-, herpes- and lentiviruses as well as new carrier cell systems, including neural and endothelial progenitor cells, have been developed. In addition, antisense technologies have advanced in recent years and entered clinical testing utilizing intratumoral administration by convection-enhanced delivery, examplified by ongoing clinical trials of intratumoral administration of antisense TGF-β. This paper summarizes some of these recent developments in molecular therapies for malignant glioma, focusing on targeted therapies using selective small molecules and gene therapy concepts.
References
Mahaley MS Jr, Mettlin C, Natarajan N, Laws ER Jr, Peace BB (1989) National survey of patterns of care for brain-tumor patients. J Neurosurg 71 (6): 826–836
von Deimling A, Louis DN, Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15 (3): 328–338
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15 (11): 1311–1333
Aaronson SA (1991) Growth factors and cancer. Science 254 (5035): 1146–1153
Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S (1991) Oncogenes and signal transduction. Cell 64 (2): 281–302
Newton HB (2003) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 3 (5): 595–614
Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA, Kuhn JG et al. (1999) Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol 17 (4): 1095–1104
Newton HB (2002) Chemotherapy for the treatment of metastatic brain tumors. Expert Rev Anticancer Ther 2 (5): 495–506
Institute NC (2006) Phase III Randomized Study of Leflunomide (SU101) Versus Procarbazine for patients with Glioblastoma Multiforme in first Relapse (study has been completed, but not yet published). Available at: http://www.clinicaltrials.gov/ct/show/NCT00003293?order=1_ClinicalTrials.gov Identifier: NCT00112788
Baselga J (2001) The EGFR as a target for anticancer therapy – focus on cetuximab. Eur J Cancer 37(Suppl 4): 16–22
Arteaga CL (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19 (18 Suppl): 32–40
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (19): 2012–2024
Newton HB (2004) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 4 (1): 105–128
Feldkamp MM, Lala P, Lau N, Roncari L, Guha A (1999) Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45 (6): 1442–1453
Rowinsky EK, Windle JJ, Von Hoff DD (1999) Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17 (11): 3631–3652
Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C et al. (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65 (16): 7462–7469
Momota H, Nerio E, Holland EC (2005) Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 65 (16): 7429–7435
Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (1): 25–35
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (1): 16–24
Farhadi MR, Capelle HH, Erber R, Ullrich A, Vajkoczy P (2005) Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J Neurosurg 102 (2): 363–370
Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J et al. (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60 (15): 4152–4160
Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK et al. (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23 (24): 5474–5483
Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, Christensen O et al. (2006) Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 17 (5): 866–873
Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C et al. (2006) Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12 (1): 144–151
Kanzawa T, Ito H, Kondo Y, Kondo S (2003) Current and Future Gene Therapy for Malignant Gliomas. J Biomed Biotechnol 2003 (1): 25–34
King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG (2005) Gene therapy and targeted toxins for glioma. Curr Gene Ther 5 (6): 535–357
Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256 (5063): 1550–1552
Stockhammer G, Brotchi J, Leblanc R, Bernstein M, Schackert G, Weber F, Ostertag C et al. (1997) Gene therapy for glioblastoma [correction of gliobestome] multiform: in vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. J Mol Med 75 (4): 300–304
Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46 (10): 5276–5281
Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN (1993) The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53 (21): 5274–5283
Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Sorensen AG, Barbier N (1999) A phase 1–2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 10 (14): 2325–2335
Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11 (17): 2389–2401
Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, Hadley D et al. (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11 (22): 1648–1658
Deglon N, Aebischer P (2002) Lentiviruses as vectors for CNS diseases. Curr Top Microbiol Immunol 261: 191–209
Galimi F, Verma IM (2002) Opportunities for the use of lentiviral vectors in human gene therapy. Curr Top Microbiol Immunol 261: 245–254
Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD et al. (1999) Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 5 (11): 1256–1263
Wang X, Zhang GR, Yang T, Zhang W, Geller AI (2000) Fifty-one kilobase HSV-1 plasmid vector can be packaged using a helper virus-free system and supports expression in the rat brain. Biotechniques 28 (1): 102–107
Summerford C, Bartlett JS, Samulski RJ (1999) AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 5 (1): 78–82
Glorioso JC, Bender MA, Goins WF, Fink DJ, DeLuca NA (1995) HSV as a gene transfer vector for the nervous system. Mol Biotechnol 4 (1): 87–99
Kofler P, Wiesenhofer B, Rehrl C, Baier G, Stockhammer G, Humpel C (1998) Liposome-mediated gene transfer into established CNS cell lines, primary glial cells, and in vivo. Cell Transplant 7 (2): 175–185
Yoshida T, Mizuno M, Taniguchi K, Nakayashiki N, Wakabayashi T, Yoshida J (2001) Rat glioma cell death induced by cationic liposome-mediated transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment. J Surg Oncol 76 (1): 19–25
Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53 (1): 83–88
Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE et al. (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 97 (23): 12846–12851
Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, Rigamonti D, Galli R et al. (2000) Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 6 (4): 447–450
Li S, Tokuyama T, Yamamoto J, Koide M, Yokota N, Namba H (2005) Potent bystander effect in suicide gene therapy using neural stem cells transduced with herpes simplex virus thymidine kinase gene. Oncogene 69 (6): 503–508
Gastl G, Gunsilius E, Petzer AL, Stockhammer G (2001) Endothelial cell progenitors for vascular targeting of tumors. Arch Pharmacol 364 (Suppl): R13
Stockhammer G, Wiegele J, Puschban Z, Stefanova N, Wechselberger J, Kaehler CM, Kostron H et al. (2002) Vascular targeting of malignant glioma using endothelial progenitor cells. Neuro-Oncology 4 (Suppl 1): 94
Stockhammer G, Obwegeser A, Kostron H, Schumacher P, Muigg A, Felber S, Maier H et al. (2000) Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol (Berl) 100 (1): 101–105
Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (6398): 845–848
Saleh M, Stacker SA, Wilks AF (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56 (2): 393–401
Machein MR, Risau W, Plate KH (1999) Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther 10 (7): 1117–1128
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (2): 277–285
O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (2): 315–328
Gale NW, Yancopoulos GD (1999) Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13 (9): 1055–1066
Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E, Scappaticci FA et al. (2005) Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 12 (5): 778–788
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (5302): 964–967
Gunsilius E, Duba HC, Petzer AL, Kahler CM, Grunewald K, Stockhammer G, Gabl C et al. (2000) Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 355 (9216): 1688–1691
Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A et al. (2001) Impaired recruitment of bonemarrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7 (11): 1194–1201
Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S, Schmutzhard E et al. (2000) Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54 (8): 1670–1676
Roth W, Weller M (1999) Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol Life Sci 56 (5–6): 481–506
Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, Bauer A et al. (1996) Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65 (3): 332–337
Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P (2006) Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev 17 (1–2): 129–139
Schlingensiepen R, Goldbrunner M, Szyrach MN, Stauder G, Jachimczak P, Bogdahn U, Schulmeyer F et al. (2005) Intracerebral and intrathecal infusion of the TGFbeta2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and Safety. Oligonucleotides 15 (2): 94–104
Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91 (6): 2076–2080
Greenfield L, Johnson VG, Youle RJ (1987) Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238 (4826): 536–539
Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3 (12): 1323
Jacobs AH, Voges J, Kracht LW, Dittmar C, Winkeler A, Thomas A, Wienhard K et al. (2003) Imaging in gene therapy of patients with glioma. J Neurooncol 65 (3): 291–305
Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R, Safer M et al. (1998) Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 58 (19): 4333–4341
Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, Kaestle C et al. (2001) Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358 (9283): 727–729
Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncol 1 (1): 44–51
Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA et al. (2005) Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med 46 (1): 114–120
Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A, Mishani E (2004) Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem 12 (13): 3421–3429
Malkin M, Mason W, Liebermann F, Hannah A (1997) Phase I study of SU101, a novel signal transduction inhibitor, in recurrent malignant glioma. Proc Am Soc Clin Oncol 16 (385a): Abstract
Malkin M, Rosen L, Lopez A, Mulay M, Cloughesy T, Hannah A (1998) Phase 2 study of SU101, a PDGFR signal transduction inhibitor, in recurrent malignant glioma. Proc Am Soc Clin Oncol 17 (390a): Abstract
Shapiro JR, Ashby L, Obbens E, DePaoli AC, Hannah A (1999) Phase I/II study of SU101 in combination with carmustine in the treatment of patients newly dignosed with malignant glioma. Neurooncology 1: 55
National Cancer Institute (NCI) C (2006) Currently open Phase I, II and III studies with different targeting substances treating patients with recurrent gliomas. Available at: http://www.clinicaltrials.gov
Wen PY, Yung WKH, K. (2002) Phase I study of STI571 (Gleevec) for patients with recurrent malignant gliomas and meningeomas (NABTC 99–08). Proc Am Soc Clin Oncol 21 (73a): Abstract
Dresemann G (2005) Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16 (10): 1702–1708
Reardon DA, Egorin MJ, Quinn JA, Rich JN Sr, Gururangan I, Vredenburgh JJ, Desjardins A et al. (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23 (36): 9359–9368
Lieberman F, Cloughesy T, Deangelis L (2003) Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningeomas progressing after radiation therapy. Proc Am Soc Clin Oncol 22 (105): Abstract
Peery TS, Reardon DA, Quinn JA (2003) Phase II of ZD1839 for patients with first relapse glioblastoma. Proc Am Soc Clin Oncol 22 (99): Abstract
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ et al. (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 (1): 133–142
Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A et al. (2006) Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neurooncol 8 (1): 67–78
Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS et al. (2005) Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 23 (27): 6647–6656
Cloughesy TF, Kuhn J, PY W (2002) Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing anti-epileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Proc. Am Soc Clin Oncol 21 (80a): Abstract
ClinicalTrials (2003) Phase II evaluation of temozolomide and farnesyl transferase inhibitor (SCH66336) for the treatment of recurrent and progressive glioblastoma multiforme. Available at: http://utm-notes-db2.mdacc.tmc.edu/mdacc/ClinicalTrialsWP.nsf/Index/DM01-258
Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K et al. (2004) Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 22 (4): 427–435
Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K et al. (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23 (4): 357–361
Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM et al. (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23 (23): 5294–5304
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hutterer, M., Gunsilius, E. & Stockhammer, G. Molecular therapies for malignant glioma. Wien Med Wochenschr 156, 351–363 (2006). https://doi.org/10.1007/s10354-006-0308-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10354-006-0308-3